Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2014

Open Access 01-12-2014 | Research article

Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study

Authors: Andrew Maguire, Beth D Mitchell, Javier Cid Ruzafa

Published in: BMC Endocrine Disorders | Issue 1/2014

Login to get access

Abstract

Background

The initial treatment strategy for patients with type 2 diabetes includes lifestyle change recommendations. When patients are not successful in controlling their blood glucose levels through healthier lifestyle pharmaceutical agents are recommended. The objective of this study is to identify determinants of initial treatment change following initiation of non-insulin antihyperglycaemic treatment (OAD) for UK patients with type 2 diabetes.

Methods

A retrospective cohort study using primary care data from the Clinical Practice Research Datalink between January 2006 and February 2011. Each patient had an OAD prescription. The main treatment pattern outcomes were discontinuation, switching, augmentation and initiation of insulin. Glycaemic control was assessed using HbA1c.

Results

63,060 patients initiated OAD therapy 2006–2010 and 3.4% were prescribed insulin during follow-up. 26% with at least four years of follow-up remained on the initial treatment. Metformin dominated (90%) in UK primary care. Around 75% had a record of HbA1c testing prior to initiating therapy. On initiating OAD, half the patients had HbA1c values >65 mmol/mol and one quarter >80 mmol/mol. The initial values of HbA1c were reduced after 12 months and remained stable. There were 15%-18% of patients whose values increased since initiating OAD. Increased baseline HbA1c is associated with increased chance of augmentation and decreased chance of discontinuation. HbA1c values at 1 year were associated with a three-fold increase in the chance of augmentation, 130% increase in the chance of switching and 14% increase in the chance of discontinuation with each 10 mmol/mol increase. Following initiation of OAD, HbA1c was reduced by an average of 16 mmol/mol during the first year.

Conclusion

There are patients for whom glycaemic control worsens and a majority remained above the recommended level, suggesting an unmet need despite the availability of many OAD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA: Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health. 2009, 63 (4): 332-336. 10.1136/jech.2008.080382.CrossRefPubMed Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA: Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health. 2009, 63 (4): 332-336. 10.1136/jech.2008.080382.CrossRefPubMed
2.
go back to reference Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine. 2008, New York: McGraw-Hill Medical Publishing Division, 17 Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine. 2008, New York: McGraw-Hill Medical Publishing Division, 17
3.
go back to reference Ismail-Beigi F: Clinical practice: glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012, 366 (14): 1319-1327. 10.1056/NEJMcp1013127.CrossRefPubMed Ismail-Beigi F: Clinical practice: glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012, 366 (14): 1319-1327. 10.1056/NEJMcp1013127.CrossRefPubMed
4.
go back to reference National Collaborating Centre for Chronic Conditions: Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). 2008, London: Royal College of Physicians National Collaborating Centre for Chronic Conditions: Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). 2008, London: Royal College of Physicians
6.
go back to reference Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ: The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006, 4: 1-10.1186/1478-7547-4-1.CrossRefPubMedPubMedCentral Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ: The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006, 4: 1-10.1186/1478-7547-4-1.CrossRefPubMedPubMedCentral
7.
go back to reference Chen SY, Siu K, Kovacs B, Stokes M, Rao P, Sander S, Boulanger L: Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Curr Med Res Opin. 2012, 28 (4): 493-501. 10.1185/03007995.2012.658909.CrossRefPubMed Chen SY, Siu K, Kovacs B, Stokes M, Rao P, Sander S, Boulanger L: Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Curr Med Res Opin. 2012, 28 (4): 493-501. 10.1185/03007995.2012.658909.CrossRefPubMed
8.
go back to reference Fowler JM: Diabetes treatment: oral agents. Clin Diabetes. 2010, 28 (3): 132-136. 10.2337/diaclin.28.3.132.CrossRef Fowler JM: Diabetes treatment: oral agents. Clin Diabetes. 2010, 28 (3): 132-136. 10.2337/diaclin.28.3.132.CrossRef
9.
go back to reference McEwan P, Evans M, Bergenheim K: A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010, 12 (7): 623-630. 10.1111/j.1463-1326.2010.01198.x.CrossRefPubMed McEwan P, Evans M, Bergenheim K: A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010, 12 (7): 623-630. 10.1111/j.1463-1326.2010.01198.x.CrossRefPubMed
10.
go back to reference Cai B, Xu W, Bortnichak E, Watson DJ: An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf. 2012, 21 (7): 770-774. 10.1002/pds.3277.CrossRefPubMed Cai B, Xu W, Bortnichak E, Watson DJ: An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf. 2012, 21 (7): 770-774. 10.1002/pds.3277.CrossRefPubMed
12.
go back to reference Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH: Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care. 2006, 12 (8): 435-440.PubMed Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH: Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care. 2006, 12 (8): 435-440.PubMed
13.
go back to reference Czernichow S, Zoungas S, Chalmers J, Patel A, Marre M, Colagiuri S, Hamet P, Li Q, Billot L: Patterns of use of glucose lowering treatments at baseline and during follow-up in ADVANCE. Diabetologia. 2010, 53 (Suppl 1): S363- Czernichow S, Zoungas S, Chalmers J, Patel A, Marre M, Colagiuri S, Hamet P, Li Q, Billot L: Patterns of use of glucose lowering treatments at baseline and during follow-up in ADVANCE. Diabetologia. 2010, 53 (Suppl 1): S363-
14.
go back to reference Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R: Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci. 2009, 31 (6): 622-626. 10.1007/s11096-009-9321-0.CrossRefPubMed Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R: Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci. 2009, 31 (6): 622-626. 10.1007/s11096-009-9321-0.CrossRefPubMed
15.
go back to reference Lamberts EJ, Nijpels G, Welschen LM, Hugtenburg JG, Dekker JM, Souverein PC, Bouvy ML: Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf. 2011, 20 (4): 351-358. 10.1002/pds.2089.CrossRefPubMed Lamberts EJ, Nijpels G, Welschen LM, Hugtenburg JG, Dekker JM, Souverein PC, Bouvy ML: Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf. 2011, 20 (4): 351-358. 10.1002/pds.2089.CrossRefPubMed
16.
go back to reference Jermendy G, Wittmann I, Nagy L, Kiss Z, Rokszin G, Abonyi-Toth Z, Katona L, Paragh G, Karadi I, Merkely B: Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit. 2012, 18 (2): CR72-CR77.CrossRefPubMedPubMedCentral Jermendy G, Wittmann I, Nagy L, Kiss Z, Rokszin G, Abonyi-Toth Z, Katona L, Paragh G, Karadi I, Merkely B: Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit. 2012, 18 (2): CR72-CR77.CrossRefPubMedPubMedCentral
17.
go back to reference Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA: Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10 (8): 638-645. 10.1111/j.1463-1326.2007.00758.x.CrossRefPubMed Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA: Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10 (8): 638-645. 10.1111/j.1463-1326.2007.00758.x.CrossRefPubMed
18.
go back to reference Haynes K, Bilker WB, Tenhave TR, Strom BL, Lewis JD: Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf. 2011, 20 (9): 948-955.PubMedPubMedCentral Haynes K, Bilker WB, Tenhave TR, Strom BL, Lewis JD: Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf. 2011, 20 (9): 948-955.PubMedPubMedCentral
19.
Metadata
Title
Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study
Authors
Andrew Maguire
Beth D Mitchell
Javier Cid Ruzafa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-14-73

Other articles of this Issue 1/2014

BMC Endocrine Disorders 1/2014 Go to the issue